P2.03-022 Impact of EGFR Mutation on Clinical Outcome of Nintedanib plus Docetaxel in Previously Treated Non- Small Cell Lung Cancer (NSCLC)

Autor:	H.J. Ahn, Y.J. Yuh, S. Hong, Jin Hyung Kang, P.I. Cheon, Y.S. Chae, Kihwan Kim, Tae-Won Jang, Yun Gyoo Lee, S.S. Lee
Rok vydání:	2017
Předmět:	Pulmonary and Respiratory Medicine Oncology medicine.medical_specialty business.industry non-small cell lung cancer (NSCLC) medicine.disease chemistry.chemical_compound chemistry Docetaxel Egfr mutation Internal medicine medicine Nintedanib Previously treated business medicine.drug
Zdroj:	Journal of Thoracic Oncology. 12:S2135-S2136
ISSN:	1556-0864
DOI:	10.1016/j.jtho.2017.09.1273
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::1a0978b5547054fe3a30f410cf4aafc3 https://doi.org/10.1016/j.jtho.2017.09.1273 Zobrazit plný text záznamu